Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infiltrates Clear all
Recruiting Phase 1Phase 2 Interventional

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05639972
View directory record Official record
Conditions
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Endocervical Adenocarcinoma, Cervical Cancer, Oropharynx Cancer, Anal Cancer, Vulvar Cancer, Penile Cancer, Vaginal Cancer
Interventions
E7 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Use of On-Q Pump for Pain Post C-Section

NCT02579629
View directory record Official record
Conditions
Pain
Interventions
Ropivacaine 0.1%, Ropivacaine 0.2%, Normal saline, On-Q ® elastomeric pump
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Serratus Anterior Plane Block Combined With Transversus Thoracic Muscle Plane Block Versus Conventional Local Anesthetic Infiltration for SICD Implantation: A Randomized Controlled Trial

NCT05092490
View directory record Official record
Conditions
Serratus Anterior Plane Block, Transversus Thoracis Plane Block, Subcutaneous ICD
Interventions
Combined serratus anterior plane block and transversus thoracis plane block, Standard local infiltration technique
Procedure
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Not applicable Interventional Results available

FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates

NCT01328873
View directory record Official record
Conditions
Pulmonary Infiltrate New
Interventions
Microbiological analysis
Other
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 21, 2026, 10:17 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

NCT02353754
View directory record Official record
Conditions
Pain
Interventions
Intrathecal morphine injection, EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Port Saint Lucie, Florida • Minneapolis, Minnesota • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Jul 21, 2026, 10:17 PM EDT
Completed No phase listed Observational

Soft Contacts Observation of Risk and Education (SCORE)

NCT03305484
View directory record Official record
Conditions
Contact Lens Complication, Contact Lens Acute Red Eye, Contact Lens Related Corneal Infiltrate (Disorder), Contact Lens-Induced Corneal Fluorescein Staining
Interventions
No intervention
Other
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years to 39 Years
Enrollment
171 participants
Timeline
2017 – 2019
U.S. locations
4
States / cities
Fullerton, California • Fort Lauderdale, Florida • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Results available

Psoas Compartment Block Versus Periarticular Local Anesthetic for Total Hip Arthroplasty

NCT02658149
View directory record Official record
Conditions
Osteoarthritis, Arthroplasty
Interventions
Ropivacaine with NaCl, Epinephrine, Morphine, Ketorolac Tromethamine, Ropivacaine
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Jul 21, 2026, 10:17 PM EDT
Recruiting Phase 2 Interventional

Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

NCT07506876
View directory record Official record
Conditions
Breast Cancer - Infiltrating Ductal Carcinoma, HER-2 Positive Breast Cancer
Interventions
Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Gresham, Oregon • Portland, Oregon • Tualatin, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 10:17 PM EDT
Not yet recruiting Phase 1 Interventional

Phase I Trial of pH Resections of GBM at VA

NCT07218367
View directory record Official record
Conditions
Glioblastoma
Interventions
pH MRI based resection of GBM
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Results available

Surgeon Infiltration QL Block Comparison

NCT03496610
View directory record Official record
Conditions
Quadratus Lumborum Block, Surgical Wound Infiltration
Interventions
Liposomal Bupivicaine, QL Block
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Jul 21, 2026, 10:17 PM EDT
Active, not recruiting Phase 1 Interventional

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

NCT06236425
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
Interventions
TBio-4101, Pembrolizumab, Platinum based chemotherapy, Cyclophosphamide, Fludarabine, Aldesleukin
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

NCT04111510
View directory record Official record
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Tumor infiltrating lymphocytes (TIL) LN-145
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars

NCT01496846
View directory record Official record
Conditions
Irreversible Pulpitis
Interventions
IANB Articaine, SUP Articaine, SUP Lidocaine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Jul 21, 2026, 10:17 PM EDT
Terminated Phase 4 Interventional Results available

A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301

NCT01507220
View directory record Official record
Conditions
Bowel Obstruction
Interventions
morphine sulfate, bupivacaine liposome extended-release injectable suspension
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics, Relative Bioavailability and Safety of INL-001 Compared to Marcaine After Open Hernioplasty

NCT03234374
View directory record Official record
Conditions
Hernioplasty
Interventions
INL-001 (bupivacaine HCl collagen implant), Marcaine 0.25% infiltration
Combination Product · Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Anniston, Alabama • Longwood, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 21, 2026, 10:17 PM EDT
Recruiting Phase 2 Interventional

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT05686226
View directory record Official record
Conditions
Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
E7 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant

NCT02232178
View directory record Official record
Conditions
Hernioplasty
Interventions
2 100mg Xaracoll implants, 3 100mg Xaracoll implants, 150mg Bupivacaine HCl injection
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Anniston, Alabama • Sheffield, Alabama • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jul 21, 2026, 10:17 PM EDT
Terminated Phase 4 Interventional Results available

A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302

NCT01507233
View directory record Official record
Conditions
Bowel Obstruction
Interventions
IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension)
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

NCT00314106
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Melanoma Reactive TIL, Cyclophosphamide, IL-2, Fludarabine, 1200 total body irradiation (TBI)
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Pembrolizumab

NCT02818920
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Neal Ready MD PhD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Lebanon, New Hampshire • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 21, 2026, 10:17 PM EDT
Active, not recruiting Phase 1 Interventional

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

NCT05902520
View directory record Official record
Conditions
HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
Interventions
DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
Biological
Lead sponsor
AgonOx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Not applicable Interventional

Does Blood Vessel Vasodilation, Caused by Focal Infiltration of Lidocaine Cause Temporary Nerve Functional Recovery for Patients with Common Peroneal Nerve Injury or Entrapment: Testing the 'Phoenix Sign' Effect Between Lidocaine (a Common Local Anesthetic) and Papaverine, a Know Vasodilator

NCT06637046
View directory record Official record
Conditions
Drop Foot
Interventions
Diagnostic procedures, Lidocaine HCl
Diagnostic Test
Lead sponsor
Stephen Barrett
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 21, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy

NCT02153918
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms, Neoplasms, Prostate
Interventions
PROSTVAC-V/TRICOM, PROSTVAC-F/TRICOM
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jul 21, 2026, 10:17 PM EDT
Withdrawn Phase 4 Interventional

Liposomal Bupivacaine After Cesarean Delivery

NCT03907813
View directory record Official record
Conditions
Pain, Postoperative, Opioid Use
Interventions
Exparel, Saline infiltration
Drug · Other
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jul 21, 2026, 10:17 PM EDT